Efficacy and safety of treating alopecia areata with ritlecitinib
ฝัง
- เผยแพร่เมื่อ 8 พ.ค. 2023
- Dr. Brett King, Associate Professor of Dermatology at Yale School of Medicine, presents the findings of his trial published in The Lancet on 13 April 2023:
Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial
Read the full paper: www.thelancet.com/journals/la...
Visit The Lancet at www.thelancet.com/journals/la...
Find out more at www.thelancet.com/?dgcid=yout...
* * *
Continue this conversation on social! Follow us today at…
/ thelancet
/ thelancetmedicaljournal
/ the-lancet - วิทยาศาสตร์และเทคโนโลยี
Is there a free clinical trials for Olumiant.
A bald guy explaing the conondrum gives me a lot of confidence...
Se acaba de aprobar GRINGO puñetas
🤣
Thank you. It means that it is better to take 50 to 30 mg, which is safer. My question to you now: How can I request this treatment because I live in the Middle East, in Saudi Arabia?
I endorse.
yes, I am also curious is this is will be shipped overseas. I just read an article on this research from Pfizer
is there any side effect for using ritlecitinib? What factors should I consider if the patient is in 15 y??
great thanks
Is this drug potentially useful for vitiligo?
If so can you tell us how and when it might be available to treat that condition?
Thanks.
It is yes, if it ends up being effective like we think it’ll probably show up in a few years for vitiligo too.
Hii..😢😢😮